From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research

B K Cassels, I Bermudez, F Dajas, J A Abin-Carriquiry, S Wonnacott

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

S-Nicotine, the principal psychoactive constituent of Nicotiana tabacum, underpins addiction to tobacco smoking. Although tobacco consumption is a leading cause of death worldwide, nicotine itself is also proposed to have potential therapeutic benefits for a diverse range of conditions. Nicotine interacts with its cognate receptors in the central nervous system to exert a predominantly modulatory influence, making neuronal nicotinic receptors attractive therapeutic targets. Here, we focus on three natural products as lead compounds for drug discovery programs, nicotine, epibatidine and cytisine, and consider the aims and limitations that shape these drug discovery endeavors.
Original languageEnglish
Pages (from-to)1657-1665
Number of pages9
JournalDrug Discovery Today
Volume10
Issue number23-24
DOIs
Publication statusPublished - Dec 2005

Fingerprint Dive into the research topics of 'From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research'. Together they form a unique fingerprint.

  • Cite this